according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

SECTION 1. IDENTIFICATION

Product name : Cefalexin Formulation Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 37 McCarville Street

Charlottetown, PE C1E 2A7

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Respiratory sensitization : Sub-category 1A

Reproductive toxicity : Category 2

Specific target organ toxicity :

- single exposure

Category 3

Specific target organ toxicity :

- repeated exposure

Category 2 (Kidney, Adrenal gland, Blood, Gastrointestinal tract)

GHS label elements

Hazard pictograms :





Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing diffi-

culties if inhaled.

H335 May cause respiratory irritation. H361f Suspected of damaging fertility.

H373 May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated

exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

and understood.

P260 Do not breathe mist or vapors.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

P284 Wear respiratory protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel

unwell.

P308 + P313 IF exposed or concerned: Get medical attention. P342 + P311 If experiencing respiratory symptoms: Call a doc-

tor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cefalexin	No data availa- ble		>= 10 - < 30 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

according to the Hazardous Products Regulations



Cefalexin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/18/2025 11474837-00003 Date of first issue: 11/26/2024 3.0

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis,

reactive airways dysfunction syndrome).

May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

May cause respiratory irritation. Suspected of damaging fertility.

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders First Aid responders should pay attention to self-protection.

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Cefalexin	15686-71-2	TWA	550 μg/m3 (OEB 2)	Internal	
	Further information: RSFN				

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection. Combined particulates and organic vapor type

Filter type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

: If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : clear

Odor : No data available

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 06/18/2025 11474837-00003 Date of first issue: 11/26/2024 3.0

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions. Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute toxicity estimate: > 2,000 mg/kg Acute oral toxicity

Method: Calculation method

Components:

Cefalexin:

: LD50 (Mouse): 1,600 - 6,200 mg/kg Acute oral toxicity

> LD50 (Dog): > 2,000 mg/kgSymptoms: Vomiting

LD50 (Monkey): > 1,000 mg/kg

Symptoms: Vomiting

LD50 (Rat): > 20,000 mg/kg

Acute toxicity (other routes of :

LD50 (Dog): > 1 g/kg

administration)

Application Route: Intraperitoneal

LD50 (Dog): > 0.1 g/kg

Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefalexin:

Assessment : Probability or evidence of high respiratory sensitization rate in

humans

Remarks : Based on data from similar materials

May cause sensitization by inhalation.

Result : Sensitizer

Remarks : Based on data from similar materials

May cause sensitization by inhalation.

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefalexin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging fertility.

Components:

Cefalexin:

Effects on fertility : Test Type: Two-generation study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

Result: May cause adverse reproductive effects., Reduced

fertility of F1 generation.

Effects on fetal development : Test Type: Development

Species: Mouse

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 400 mg/kg body weight Remarks: No significant adverse effects were reported

Maternal toxicity observed.

Test Type: Development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 1,200 mg/kg body weight Remarks: No significant adverse effects were reported

Maternal toxicity observed.

Reproductive toxicity - As-

sessment

: Suspected of damaging fertility.

STOT-single exposure

May cause respiratory irritation.

Components:

Cefalexin:

Routes of exposure : Inhalation

Assessment : May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated exposure.

Components:

Cefalexin:

Target Organs : Kidney, Adrenal gland, Blood, Gastrointestinal tract

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cefalexin:

Species : Rat

NOAEL : < 160 mg/kg

Application Route : Oral

Target Organs : Kidney, Adrenal gland, Blood

Symptoms : Vomiting, Diarrhea, Kidney disorders, Blood disorders

Species : Dog

NOAEL : < 160 mg/kg

Application Route : Oral

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

Target Organs : Kidney, Adrenal gland, Blood

Symptoms : Vomiting, Diarrhea, Blood disorders, Kidney disorders

Species : Monkey NOAEL : < 160 mg/kg

Application Route : Oral

Target Organs : Kidney, Adrenal gland, Blood

Symptoms : Vomiting, Diarrhea, Blood disorders, Kidney disorders

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefalexin:

Inhalation : Target Organs: Respiratory Tract

Remarks: May cause irritation of respiratory tract.

May cause sensitization by inhalation.

Ingestion : Target Organs: Gastrointestinal tract

Symptoms: The most common side effects are:, Nausea, Vomiting, Abdominal pain, Diarrhea, liver function change,

blood effects

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cefalexin:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

UN/ID No. : UN 3334

Proper shipping name : Aviation regulated liquid, n.o.s.

(Cefalexin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen:

: 964

ger aircraft)

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan): ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 06/18/2025 Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the

according to the Hazardous Products Regulations



Cefalexin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 3.0 06/18/2025 11474837-00003 Date of first issue: 11/26/2024

SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8